All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
ECHELON-3 subgroup analysis: Brentuximab vedotin + lenalidomide + rituximab for older patients with R/R DLBCL
Bookmark this article
|
Despite recent treatment advances, there remains an unmet need for safe, effective, and durable therapies for patients with R/R DLBCL. Brentuximab vedotin (BV) is an anti-CD30 ADC with demonstrated efficacy and safety when combined with lenalidomide (Len) and rituximab (R) in heavily pretreated populations. The phase III ECHELON-3 trial (NCT04404283) investigated the efficacy and safety of BV+Len+R vs Pbo+Len+R in patients with R/R DLBCL who received ≥2 prior lines of systemic therapy. Results from a subgroup analysis of findings in older patients aged ≥65 years (n = 155) and ≥75 years (n = 86) were presented at the 66th ASH Annual Meeting and Exposition by Bartlett.1 |
| Key learnings |
| OS was improved with BV+Len+R vs Pbo+Len+R, at 15.9 months vs 8.5 months (p = 0.0043) in patients aged ≥65 years and 21.5 months vs 8.5 months (p = 0.0189) in patients aged ≥75 years. |
| PFS was longer with BV+Len+R vs Pbo+Len+R, at 5.7 months vs 2.8 months (p = 0.0003) in patients aged ≥65 years and 7.1 months vs 4.0 months (p = 0.0136) in patients aged ≥75 years. |
| ORR was higher with BV+Len+R vs Pbo+Len+R, at 70.9% vs 46.1% (p = 0.0020) in patients aged ≥65 years and 70.8% vs 52.6% (p = 0.1159) in patients aged ≥75 years. CR rates were 45.6% vs 19.7% and 45.8% vs 26.3% in patients aged ≥65 and ≥75 years, respectively. |
| The treatment was well-tolerated, with no clinically meaningful safety trends reported in any age group, suggesting that BV+Len+R could be a viable therapeutic option for the treatment of older patients with R/R DLBCL. |
Abbreviations: ADC, antibody–drug conjugate BV, brentuximab vedotin; CR, complete response; DLBCL, diffuse large B-cell lymphoma; Len, lenalidomide; OS, overall survival; ORR, overall response rate; Pbo, placebo; PFS, progression-free survival; R, rituximab; R/R, relapsed/refractory.
- Bartlett NL. Outcomes in older patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) from the ECHELON-3 study. Poster #4483. American Society of Hematology (ASH) Annual Meeting and Exposition; Dec 10, 2024; San Diego, US.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
82 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox